Nzira yekurapa COVID-19? Kupfapfaidza nasal i 93%

Mushonga wemhuno wemhuno wakagadziridzwa kuti ukwidziridze immune system yemunhu kurwisa chikosoro uye furuwenza yakaratidza kubudirira zvakanyanya mukudzikisa COVID-19 hutachiona hwekudzokorora mhinduro, yakaburitswa nhasi, inoratidza.

Chigadzirwa chitsva ichi, INNA-051, chiri kuvandudzwa nekambani yeAustralia biotech, Ena Respiratory, yakaderedza kudzokororwa kwehutachiona kusvika 96 muzana muongororo yegoridhe-yemhando yemhuka inotungamirwa nePublic Health England's (PHE) Mutevedzeri Mukuru, Muzvinafundo Miles Carroll uye yakaburitswa nhasi. pane biomedical pre-kuburitswa tsvagiridzo saiti, medRxiv.

Iyo INNA-051 komputa inoshanda nekukurudzira immune system yemukati, mutsara wekutanga wedziviriro kubva pakupinda kwehutachiona mumuviri. Nekuwedzera simba rekudzivirira muviri nenzira iyi neINNA-051 isati yatapukirwa, kugona kwehutachiona hweCCIDID-19 kutapurira mhuka uye kudzokorora kwakaderedzwa zvakanyanya chidzidzo chePHE chakaratidza. Chidzidzo ichi chinopa humbowo hwekuti INNA-051 inogona kushandiswa senzira yekuzvimiririra yekudzivirira hutachiona hwehutachiona, hunoenderana nezvirongwa zvejekiseni.

"Takashamiswa nemabatirwo akaitwa kurapwa kwedu," anodaro Ena Respiratory Managing Director, Dr Christophe Demaison. "Nekuwedzera maitiro ekudzivirira ekudzivirira ekudzivirira nekurapa kwedu, taona kukurumidza kupera kwehutachiona."

“Kana vanhu vakaita nenzira yakafanana, betsero dzokurapwa dzinopetwa kaviri. Vanhu vakafumurwa hutachiona vangangochibvisa nekukurumidza, nekurapa vachiona kuti chirwere hachifambire mberi kupfuura zviratidzo zvinyoro. Izvi zvinonyanya kukosha kune avo vanotambura munharaunda. Pamusoro pezvo, kukurumidza kwemhinduro iyi kunoreva kuti vanhu vane hutachiwana havakwanise kuipfuudza, zvichireva kukurumidza kumiswa kutapurirana munharaunda. ”

Ena Respiratory yakasimudza AU $ 11.7m kubva kune vanoisa mari kuAustralia uye, zvichienderana nekubudirira zvidzidzo zvehupfu uye kubvumidzwa kwemutemo, kambani inogona kunge yakagadzirira kuyedza INNA-051 mumiedzo yevanhu mukati memwedzi isingasviki mina. 

Kudyara nerutsigiro mukugadzira rivhi rekurapa kwakatungamirwa kubva kuAustralia Medical Research Commercialization Fund (MRCF), homwe huru yeAustralia yekudyara sainzi yehupenyu inotungamirwa naBrandon Capital, pamwe nekudyara kubva kuyunivhesiti yekushambadzira homwe Uniseed. Kambani iyi iri kutsvaga imwe mari nekuchimbidza kuti ikurumidze kuvandudza kiriniki yenasal spray uye kugovera pasi rose. 

Dr Chris Nave, CEO weMRCF uye muvambi weBrandon Capital, vanoti mhedzisiro iyi inovimbisa zvakanyanya zvinoreva kuti INNA-051 inonakidza pamberi muhondo yekukunda COVID-19. "Tiri kuita zvese zvatinogona kutsigira Ena Respiratory uye kuda kwayo kuchengetedza imwe mari kuti ikurumidze kusimudzira uye kuyedzwa kwekurapa muvanhu. Nepo vaccine iriyo mhinduro yakakosha mukurwisa COVID-19, hurumende dzinofanirwa kunge dzichigadzira nzira dzakasiyana dzekurapa kuti dzive nechokwadi chekuti dzine sarudzo dzakasiyana, kana vaccine ikatadza kana kutora nguva kuti igadziriswe.

INNA-051 imorekuru diki rekugadzira uye raizozvifambisa pachako kuburikidza nekupfapfaidza nemhino kuri nyore, inotorwa kamwe kana kaviri pasvondo, kurapwa kuchingotora kukurumidza kuitika. Kana miedzo yevanhu ikabudirira uye, nekupihwa kusati kwamboitika kwemishonga yekurwisa COVID-19, iyi prophylactic immune modulation therapy inogona kukurumidza kugadzirwa pamwero uye kuwanikwa kuti ishandiswe munguva pfupi.

"Ichi chiitiko chakakosha apo nyika inomhanya kutsvaga mhinduro yekumisa kutapurirana kweCCIDID-19 uye kutapukira kwevanhu vari panjodzi," anodaro Muzvinafundo Roberto Solari nyanzvi yekufema, chipangamazano weEna Respiratory uye Purofesa anoshanyira kuImperial College London. "Chinonyanya kufadza kugona kweINNA-051 kudzikisa zvakanyanya huwandu hwehutachiona mumhino nepahuro, zvichipa tariro yekuti kurapwa uku kunogona kuderedza kutapurirana kweCCIDID-19 nevanhu vane hutachiona, kunyanya avo vanogona kunge vari presymptomatic kana asymptomatic nekudaro vasingazive kuti vane hutachiona. ,” Purofesa Solari anodaro.

INNA-051 inopa tariro chaiyo kune avo vari kumberi kurwa neCCIDID-19, anodaro Dr Chris Smith, Ena Respiratory Board Director, uye Senior Investment Manager kuBrandon Capital. "Kurapa uku kunopa mukana wakakura kuchengetedza vanotambura zvakanyanya, kusanganisira avo vane mamiriro ekufema aripo uye vakwegura, uko mishonga yekudzivirira inogona kusashanda." 

INNA-051 yakanga iri mubudiriro isati yatanga kweCCIDID-19 kusimudzira kuramba kune yakakura yekufema hutachiona hwehutachiona. Kusiyana nemajekiseni anonangidzirwa kune imwe mhando, INNA-051, yakagadzirirwa kushanda kune ese marudzi ezvirwere zvekufema. 

"Kurapwa kwedu kwemhuno kune mukana unoshamisa wekurwisa COVID-19 uye nedenda remangwana," vanoenderera mberi Dr Smith. Isu tinoziva kuti majekiseni anowanzo inzira inoyevedza mukurwisa zvirwere zvehutachiona hwekufema, asi nzira iyi inowanzouya nematambudziko sezvo majekiseni anokonzeresa mhinduro yakanangana neiyo inogadzirisa immune system iyo inogona kusashanda kurwisa hutachiona mune ramangwana. INNA-051 inoshandisa iyo isiri-chaiyo yekuzvarwa immune mhinduro zvichireva kuti inoshanda kurwisa huwandu hwakawanda hwehutachiona. " 

"Semunhu akatanga kudyara mari padivi peUniseed, iyo MRCF yakaona mukana mukuru muINNA-051, nguva yeCCIDID-19 isati yasvika, kubata hutachiona hwekufema, sezvatiri kuitika pari zvino, kunyangwe takatarisana nefuruwenza," Dr Nave vanoenderera mberi. . "Isu tiri kufara nekugona kutungamira kuedza kurwisa COVID-19. Kurapwa kwacho kune mukana wakakura, kwete kurwisa denda iri chete asiwo kuita basa rakakosha mukubuda kwehutachiona hwekufema. "

Vanyori vechidzidzo ichi vanosanganisira masayendisiti kubva kuPublic Health England (PHE), Ena Respiratory, uye anotungamira masangano ekutsvagisa eAustralia, Hunter Medical Research Institute, Newcastle uye University of Melbourne. 

Mukuru weUniseed Dr Peter Devine akawedzera kuti, "Iyi mibairo inonakidza uye inoratidza kushanda kwekiriniki kwemushonga weEna mukurapa COVID-19 izvo zvingangoda nzira dzakawanda dzekurapa. Inosimbisawo kukosha kwekufambisa kushambadzira kwekutanga kwetsvagiridzo, iyo inogona kuenderera mberi nekugadzira nyika. "

About Ena Respiratory

Ena Respiratory ikambani inotsigira zvizere yeEna Therapeutics, ine chinangwa chekushandura marapirwo nekudzivirira kwezvirwere zvekufema muvanhu vari panjodzi.

Ena Respiratory iri kugadzira novel, synthetic innate immunomodulators yekudzivirira yekufema hutachiona hwehutachiona uye hwehutachiona. Iyo kambani inogara muMelbourne uye Sydney, Australia. Ena Therapeutics yakachengetedza Series A investimendi kubva kuBrandon Capital inotungamirwa Medical Research Commercialization Fund (MRCF) uye Uniseed.

Nezve INNA-051

Ena Respiratory's lead candidate, INNA-051 is a synthetic, pegylated TLR2/6 agonist. INNA-051 yakagadziridzwa kuendesa topical kunzira dzemhepo (kuburikidza nenasal spray kamwe/kaviri pasvondo) kuitira kunanga nzvimbo yekutanga yehutachiona hwehutachiona hwekufema, kusanganisira COVID-19, furuwenza uye rhinovirus. Topical kufema manejimendi eEna Respiratory's pegylated TLR2/6 agonists inokonzeresa kuvhurwa kweakati wandei makiyi, emukati ekudzivirira ekudzivirira ekudzivirira maitiro anobatanidzwa muantiviral prophylaxis. INNA-051 yakavakirwa pane zvakawanikwa naProfessor Fellow David Jackson nechikwata chake. Muzvinafundo Jackson anotungamira marabhoritari kuDhipatimendi reMicrobiology uye Immunology paPeter Doherty Institute for Infection and Immunity, University of Melbourne. 

Kushanda kwehutachiona hwehutachiona hweEna Respiratory's pegylated TLR2/6 agonists kwakaratidzwa mumhando dzemhuka dzehutachiona hwekufema, kusanganisira furuwenza uye rhinovirus (inotonhora) uye mhando dzechipiri dzehutachiona hwehutachiona.

INNA-051 kushanda kweCCIDID-19 kwakasimbiswa mune ferret dambudziko modhi nechikwata chinotungamirwa naProfessor Miles Carroll kuPublic Health England. Muchidzidzo ichi INNA-051 yakaitwa seprophylaxis. Mune yakaringana dose regimen, mushure memazuva mashanu mushure mekuratidzwa kuCCIDID-5, INNA-19 mhuka dzakarapwa dzakange dzadzikira zvakanyanya hutachiona muhuro swabs (051% kuderedzwa) nekugezeswa kwemhino (96% kuderedza) zvichienzaniswa nemhuka dzisina kurapwa, zvisinei. mazinga akanyanya ehutachiwana (anosvika miriyoni mashanu evhairasi particles akaiswa muzvidzidzo izvi).

Nezve Medical Research Commercialization Fund (MRCF) uye Brandon Capital Partners 

Brandon Capital Partners ikambani yemari inobata homwe yeMedical Research Commercialization Fund (MRCF), Australia neNew Zealand homwe yekudyara sainzi yehupenyu. MRCF mubatanidzwa wakasarudzika pakati pehomwe huru dzeAustralia dzekupedza makore, hurumende dzeAustralia neNew Zealand, hurumende dzeAustralia uye masangano anopfuura makumi mashanu anotungamira ekutsvagisa zvekurapa uye zvipatara zvekutsvagisa. Iyo MRCF inotsigira kusimudzira uye kushambadzira kwekutanga-nhanho biomedical zvakawanikwa zvichibva kunhengo dzemasangano ekutsvagisa, zvichipa zvese mari uye hunyanzvi hwekutungamira budiriro yekurapa kutsva. MRCF yatsigira makambani ekutanga makambani anodarika makumi mana nemashanu, mazhinji acho akavambwa neMRCF. 

About Uniseed

Uniseed ndiyo homwe yeAustralia yakarebesa inomhanyisa nhanho yekutanga kushambadzira inoita mari mukutsvaga kubva kumasangano mashanu eAustralia anotungamira ekutsvagisa - The University of Queensland, The University of Sydney, The University of New South Wales, The University of Melbourne and the CSIRO. Uniseed ihomwe yemutual fund, yemasangano ekutsvagisa, yemasangano ekutsvagisa. Homwe iyi inofambisa kutengeserana kwevabatsiri vayo vanotsvagisa pfuma yehungwaru inovimbisa uye inochengetedza mari yakanangwa muzvigadzirwa uye matekinoroji. Uniseed yakatsigira makambani ekutanga makumi mashanu nemanomwe kusvika pari zvino, ari iye anodyara mbeu mune mazhinji aya.

More: www.uniseed.com